Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Lucia, Tornaghi"'
Autor:
Anna Franceschino, Lucia Tornaghi, Valerie Benemacher, Sarit Assouline, Carlo Gambacorti-Passerini
Publikováno v:
Haematologica, Vol 93, Iss 2 (2008)
Imatinib, the treatment of choice for chronic myeloid leukemia, is generally well tolerated. We present here data from a retrospective analysis on metabolic abnormalities occurring during therapy which show increased creatine kinase, inverse creatine
Externí odkaz:
https://doaj.org/article/29094dda61444e6cb65d6c5b828101e9
Autor:
Monica Fumagalli, Carlo Gambacorti-Passerini, Federica Colnaghi, Luisa Ponchio, Andrea Biondi, Lucia Tornaghi, Giovanni Giudici, Elena Maria Elli, Maria Dassi, Matteo Parma, Pietro Pioltelli, Paolo Perseghin, Enrico Pogliani
Publikováno v:
Transfusion. 45:1214-1220
BACKGROUND: Imatinib mesylate (IM) was introduced in chronic myeloid leukemia (CML) treatment in the late 1990s and substantially changed the therapeutic approach to the disease, by inducing complete cytogenetic response (CCR) in approximately 60 per
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4f7f7fd14ac1d356beb4f19b2cdb543
https://doi.org/10.1111/j.1537-2995.2005.00175.x
https://doi.org/10.1111/j.1537-2995.2005.00175.x
Autor:
Lucio Gnessi, Giovanni Spera, Sabrina Basciani, Carlo Gambacorti-Passerini, Stefania Mariani, Marianna Sassone, Lucia Tornaghi, Raffaella Buzzetti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d506745e03d309344ea13d7fb3f9f2de
http://hdl.handle.net/10281/33147
http://hdl.handle.net/10281/33147
Autor:
Lucia Tornaghi, Carlo Gambacorti-Passerini, Anna Franceschino, Sarit Assouline, Valerie Benemacher
Imatinib, the treatment of choice for chronic myeloid leukemia, is generally well tolerated. We present here data from a retrospective analysis on metabolic abnormalities occurring during therapy which show increased creatine kinase, inverse creatine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7619ca065d2f85a81afd48ddacfec79
http://hdl.handle.net/10281/552
http://hdl.handle.net/10281/552
Autor:
Elena Marangon, Maurizio D'Incalci, Lucia Tornaghi, Enrico Pogliani, Anna Franceschino, Carlo Gambacorti-Passerini, Massimo Zucchetti
Publikováno v:
Blood. 109(5)
Imatinib substantially changed the course and prognosis of chronic myeloid leukemia (CML). As a consequence, several female CML patients decided to become pregnant. In this setting, an unsolved clinical question regards the potential exposure of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::501c05ca6b8b85335844b9725643d2d2
https://pubmed.ncbi.nlm.nih.gov/17312003
https://pubmed.ncbi.nlm.nih.gov/17312003
Autor:
Anna, Franceschino, Lucia, Tornaghi, Rocco, Piazza, Enrico, Pogliani, Carlo, Gambacorti Passerini
Publikováno v:
Haematologica. 91
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1eec6178932a56f2b873e2e1387ec851
https://pubmed.ncbi.nlm.nih.gov/16785120
https://pubmed.ncbi.nlm.nih.gov/16785120
Autor:
Enrico Maria Pogliani, Gianmarco Corneo, Rocco Piazza, Anna Franceschino, Lucia Tornaghi, Carlo Gambacorti-Passerini, Vera Magistroni, Federica Colnaghi, Federica Andreoni
Despite the positive results achieved by Imatinib mesylate (Imatinib) in the treatment of chronic myeloid leukemia (CML), over the past several years, Imatinib does not eradicate the leukemic clone. The long-term duration of response to the drug is n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f257f8f5b0c31c5761cc0fdf51ed4f8b
http://hdl.handle.net/10281/15094
http://hdl.handle.net/10281/15094
Autor:
Silvia Bungaro, Rocco Piazza, Enrico Pogliani, F Colnaghi, Vera Magistroni, Carlo Gambacorti-Passerini, Gianmarco Corneo, Anna Franceschino, Federica Andreoni, Lucia Tornaghi, Marileila Varella-Garcia
Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d23ba1244e58081e92ccee11d745ba80
http://hdl.handle.net/10281/12871
http://hdl.handle.net/10281/12871
Autor:
Francesca Pecori-Giraldi, Enrico Maria Pogliani, Nadia Cambiaghi, Francesco Cavagnini, Lucio Gnessi, Gianmarco Corneo, Pellegrino Rossi, Luigi Mariani, Carlo Gambacorti-Passerini, Lucia Tornaghi
Publikováno v:
Lancet (London, England). 361(9373)
Summary cKit and platelet-derived growth-factor receptor (PDGFR) are receptor tyrosine kinases expressed in the testis, are involved in testosterone production, and are inhibited by imatinib. We measured hormone concentrations in 38 men receiving ima
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::957cfca0b444c922a05ee436b1675766
https://pubmed.ncbi.nlm.nih.gov/12801741
https://pubmed.ncbi.nlm.nih.gov/12801741